Seroxo Limited

Leukocyte ImmunoTest™(LIT™) is a ten-minute finger-prick point-of-care (POC) blood-test that assesses host-response to infection through measurement of real-time neutrophil function (RTNF). The patented assay has been shown to be superior to current biomarkers for several clinical applications, including i.) sepsis, where LIT is more responsive for monitoring clinical progression compared with current biomarkers such as neutrophil-count or C-reactive-protein (CRP), and ii.) cancer, where risk-stratification and early detection of metastatic-cancer have been demonstrated in three clinical trials. With a portable handheld luminometer (reader) and AI-enabled software incorporating both LIT-scores and conventional markers, LIT will lead to radically improved outcomes for sepsis patients.